<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=L%27Hermitte</id>
	<title>L'Hermitte - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=L%27Hermitte"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=L%27Hermitte&amp;action=history"/>
	<updated>2026-10-03T17:24:58Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=L%27Hermitte&amp;diff=142&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=L%27Hermitte&amp;diff=142&amp;oldid=prev"/>
		<updated>2012-01-28T02:42:59Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;'''The administration of hyperbaric oxygen to patients with multiple sclerosis did not improve symptoms or prevent deterioration.''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Bottom Line:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. No evidence of benefit in multiple sclerosis from the application of hyperbaric oxygen &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Trend to worse performance on disability scale after hyperbaric oxygen &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by''': Mike Bennett, Dept of Diving and Hyperbaric Medicine, &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Prince of Wales Hospital, Sydney; Friday, 24 December 1999 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Scenario:''' A patient with chronic progressive multiple sclerosis. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Three-part Question:''' For patients with chronic stable or progressive multiple sclerosis, does the administration of hyperbaric oxygen, compared to no specific treatment, result in any amelioration of the symptoms and signs of MS, or prevent further deterioration? &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' Hyperbaric oxygenation, multiple sclerosis &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Double-blinded controlled trial with intention-to-treat. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Patients with either stable or progressive multiple sclerosis. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Control group (N = 16; 15 analysed): 60 minutes breathing 10.5%oxygen at 2ATA daily, 5 days each week for a total of 20 treatments. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Experimental group (N = 34; 34 analysed): As above plus 100% oxygen at 2ATA or 2.3ATA. The latter patients were also given diazepam 5mg pre-treatment. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Evidence:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Outcome''' &amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Time to Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Control group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''HBO group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Relative risk reduction''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Absolute risk reduction''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''NNT''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Disability Status Score Worse''' &amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 weeks &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.118 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.12 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-8 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''95% CIs:''' &amp;lt;/span&amp;gt; ||   ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.23 to -0.11 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-105 to -4 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Disability Status Score Worse''' &amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;6 months &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.333 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.5 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-50% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.17 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-6 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-100% to 37% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.46 to 0.13 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNT'''8 to INF NNH=2 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Symptomatic Improvement''' &amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 weeks &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.600 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.441 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;27% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.16 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style=&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;6 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''95% CIs:''' &amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-23% to 76% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.14 to 0.46 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNT'''2 to INF NNH=7 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Comments:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Some unexplained loss to follow-up and the groups are unequal, ?true randomisation. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. A trend to worse outcome in the active groups. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. 18 authors! &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Expiry date:''' January 2015 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''References:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1.L'Hermitte F, Roullet E, Lyon-Caen O et al. Hyperbaric oxygen treatment of chronic multiple sclerosis. Results of a placebo-controlled, double-blind study in 49 patients. Revue de Neurologie 1986; 142:201-206. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:http://www.hboevidence.com/_themes/copy-of-sumi-painting/sumhorsa.gif|center|external]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 22px; text-align: center;&amp;quot;&amp;gt;'''[[Multiple Sclerosis  |  BACK]]'''&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>